Ocular Therapeutix (OCUL) PT Lowered to $17 at BofA Securities, PT $17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Raymond James Reiterates Strong Buy Rating on Ocular Therapeutix (OCUL), PT $19
March 3, 2025 11:47 AM ESTRaymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL)
The analyst comments "Monday before Market Open, Ocular Therapeutix reported 4Q24 results. Management hosted a call to discuss progress. The company reported $17.1M in total revenue vs. our estimated $17.8M and diluted EPS of $(0.29) vs. our projected $(0.26). Revenues... More
Ocular Therapeutix (OCUL) Misses Q4 EPS by 4c
March 3, 2025 7:10 AM ESTOcular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $17.08 million versus the consensus estimate of $17.21 million.
For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.
... More